Index · Artikel · FDA approves Roche skin cancer drug

FDA approves Roche skin cancer drug

2012-01-30 5
   
Advertisement
résumén">U.S. health regulators on Monday approved Roche's pill to treat an advanced form of the most common form of skin cancer, known as basal cell carcinoma. The drug, Erivedge, which was co-developed by Curis Inc, was given a green light by the Food
Advertisement

FDA approves Roche skin cancer drug


n">U.S. health regulators on Monday approved Roche's pill to treat an advanced form of the most common form of skin cancer, known as basal cell carcinoma.

The drug, Erivedge, which was co-developed by Curis Inc, was given a green light by the Food and Drug Administration more than a month ahead of the expected March 8 decision date. It was approved for use by adults whose cancer cannot be treated with surgery or radiation or whose disease has spread to other parts of the body or returned following surgery.

Erivedge, known chemically as vismodegib, is the first drug to gain FDA approval for advanced basal cell carcinoma. Curis, which earned a $10 million milestone payment as a result of the approval, is entitled to royalty payments on sales of the drug.

"Today's approval provides a new treatment for people with advanced basal cell carcinoma who, until now, had no approved medicines to help shrink disfiguring or potentially life-threatening lesions," Hal Barron, Roche chief medical officer, said in a statement.

The drug, which is taken once a day, is expected to cost about $7,500 a month, with an estimated 10-month course of treatment totaling about $75,000, Curis said in a regulatory filing.

Roche is awaiting an approval decision on the drug in Europe.

Basal cell carcinoma is generally a slow-growing and painless form of skin cancer that starts in the top layer of the skin and develops on areas that are regularly exposed to sunlight or other ultraviolet radiation.

Erivedge works by inhibiting a signaling pathway that is active in most basal cell cancers and only in a few normal tissues, such as hair follicles.

The drug was approved with a warning alerting patients and health-care professionals of the potential risk of death or severe birth effects to a fetus. Pregnancy status must be verified prior to the start of Erivedge treatment, the FDA said.

Curis shares were down 16 cents, or 3 percent, at $5.02 on Nasdaq. Roche shares closed off 1.2 percent in Switzerland.

(Reporting by Bill Berkrot; editing by Mark Porter and Gunna Dickson)

  • FDA approves Roche skin cancer drug Zelboraf

    FDA approves Roche skin cancer drug Zelboraf
    WASHINGTON U.S. drug regulators on Wednesday approved a targeted skin cancer drug from Roche Holding along with its diagnostic test, an advance in personalized health care. The Food and Drug Administration was two months ahead of schedule in approvin
    2011-08-17 ROCHEZELBORAF
  • FDA approves Roche skin cancer drug

    FDA approves Roche skin cancer drug
    n">U.S. health regulators on Monday approved Roche's pill to treat an advanced form of the most common form of skin cancer, known as basal cell carcinoma. The drug, Erivedge, which was co-developed by Curis Inc, was given a green light by the Food
    2012-01-30 ROCHEAPPROVAL
  • Novartis gets FDA approval for skin cancer drug combination

    Novartis gets FDA approval for skin cancer drug combination
    n">Novartis AG said on Friday it received the U.S. Food and Drug Administration's regular approval for a drug combination to treat an aggressive form of skin cancer. The FDA approved Tafinlar and Mekinist for treatment of metastatic melanoma based
    2015-11-20 FDANOVARTIS
  • Roche gets Swiss approval for skin cancer drug

    Roche gets Swiss approval for skin cancer drug
    ZURICH Swiss drugmaker Roche Holding AG has received Swiss approval for Erivedge, the first medicine for people with advanced forms of basal cell carcinoma, the most common skin cancer. Roche, the world's largest maker of cancer drugs, said about 10,
    2013-06-11 ROCHECARCINOMA
  • Roche skin cancer drug meets main goal in combination study

    Roche skin cancer drug meets main goal in combination study
    ZURICH An experimental drug from Roche helped people with an advanced form of skin cancer live longer without their disease worsening when used in combination with another treatment, the Swiss drugmaker said on Monday. Pharmaceutical companies are lo
    2014-07-14 ROCHEDRUGS
  • U.S. FDA approves Gilead blood cancer drug Zydelig

    U.S. FDA approves Gilead blood cancer drug Zydelig
    n">The U.S. Food and Drug Administration said on Wednesday it has approved Gilead Sciences Inc's Zydelig, a drug to treat three types of blood cancer. The FDA approved the use of Zydelig in combination with Roche AG's Rituxan for patients with rel
    2014-07-23 CANCERDRUGSAPPROVAL
  • FDA approves Novartis's advanced skin cancer drug

    FDA approves Novartis's advanced skin cancer drug
    n">The U.S. Food and Drug Administration approved Novartis AG's oral pill to treat the most common form of advanced skin cancer. The drug, Odomzo, carry a boxed warning to alert the risks that it may cause death or severe birth defects in a develo
    2015-07-24 FDANOVARTIS
  • FDA approves Roche's Cotellic for combination skin cancer therapy

    FDA approves Roche's Cotellic for combination skin cancer therapy
    ZURICH The U.S. Food and Drug Administration on Tuesday approved Swiss drugmaker Roche's Cotellic to be used in combination with the company's Zelboraf drug to treat BRAF V600 mutation-positive advanced melanoma. Roche is counting on the addition of
  • FDA approves Roche leukemia drug Gazyva

    FDA approves Roche leukemia drug Gazyva
    n">U.S. regulators said on Friday they approved a new treatment from Roche Holding AG for patients with chronic lymphocytic leukemia (CLL) who have not previously been treated for one of the most common forms of blood cancer. The U.S. Food and Dru
    2013-11-01 ROCHELEUKEMA
  • Roche gets accelerated U.S. approval for lung cancer drug

    Roche gets accelerated U.S. approval for lung cancer drug
    n">U.S. health regulators on Friday said they have granted accelerated approval to Roche Holding's drug for advanced lung cancer in patients with a specific genetic mutation. The drug, alectinib, to be sold under the brand name Alecensa, was appro
    2015-12-11 ROCHEAPPROVAL
  • U.S. FDA approves Roche's immunotherapy for bladder cancer

    U.S. FDA approves Roche's immunotherapy for bladder cancer
    n">Roche Holding AG won earlier-than-expected U.S. approval on Wednesday for its bladder cancer drug Tecentriq, the company's first entry in a new class of cancer drugs that work by harnessing the body's own immune system. Tecentriq is the first n
    2016-05-18 FDAROCHE
  • Positive skin cancer drug data boosts Roche

    Positive skin cancer drug data boosts Roche
    ZURICH Roche's new cancer drug vismodegib could help patients with a potentially fatal skin cancer type, positive mid-stage trial results showed, going some way to lift confidence in the drugmaker after a rough 2010. Roche is struggling to find its f
    2011-03-21 ROCHE
  • FDA approves two Glaxo melanoma drugs

    FDA approves two Glaxo melanoma drugs
    n">U.S. health regulators on Wednesday approved a pair of GlaxoSmithKline Plc drugs to treat advanced melanoma - the deadliest form of skin cancer - in patients with specific genetic mutations. It also approved a diagnostic test to detect the muta
  • Roche skin cancer combination therapy gets EU panel backing

    Roche skin cancer combination therapy gets EU panel backing
    ZURICH Roche is expecting the European Commission this year to issue a final decision on a drug combination to treat advanced skin cancer, based on a drug panel's positive opinion made public on Friday. The European Union's Committee for Medicinal Pr
    2015-09-25 CANCERROCHECOMBO
  • FDA approves Roche Ebola test for emergency use

    FDA approves Roche Ebola test for emergency use
    ZURICH Roche Holding AG said U.S. health regulators have approved its Ebola test for emergency use in response to the world's worst outbreak of the disease in West Africa. The U.S. Food and Drug Administration (FDA) has approved Roche's LightMix Ebol
    2014-12-29 HEALTHROCHEEBOLA
  • ImmunoGen, Roche gastric cancer drug fails study

    ImmunoGen, Roche gastric cancer drug fails study
    n">ImmunoGen Inc said the gastric cancer drug it is developing with Roche Holding AG did not meet the main goal in a large study. ImmunoGen entered into a royalty purchase agreement with Roche for Kadcyla this year. Kadcyla, approved in 2013 for t
    2015-10-22 STUDYROCHE
  • Common skin cancer drug smoothes wrinkles: study

    Common skin cancer drug smoothes wrinkles: study
    CHICAGO A cream used to treat the early signs of skin cancer may erase wrinkles and leave behind younger-looking skin, U.S. researchers said on Monday. They said Valeant Pharmaceuticals' cream Efudex, which is used to treat actinic keratoses, a preca
    2009-06-16 CANCERSKIN
  • FDA rejects Aveo kidney cancer drug, asks for additional trial

    FDA rejects Aveo kidney cancer drug, asks for additional trial
    n">Aveo Oncology said the Food and Drug Administration denied approval for its experimental kidney cancer drug citing inconsistent trial results and asked for an additional study. In a complete response letter to the company, the health regulator
    2013-06-10 FDAKIDNEYCANCERAVEO
  • U.S. FDA approves GlaxoSmithKline's HIV drug Tivicay

    U.S. FDA approves GlaxoSmithKline's HIV drug Tivicay
    WASHINGTON The U.S. Food and Drug Administration said on Monday it has approved GlaxoSmithKline Plc's drug Tivicay to treat the most common strain of HIV, the virus that causes AIDS. The once-daily drug, known generically as dolutegravir, belongs to
  • FDA approves Sanofi/Regeneron cholesterol drug with limits

    FDA approves Sanofi/Regeneron cholesterol drug with limits
    WASHINGTON The U.S. Food and Drug Administration approved a potent new cholesterol-lowering drug from Sanofi SA (SASY.PA) and Regeneron Pharmaceuticals Inc (REGN.O) on Friday but limited its approved use to patients with a hereditary form of the cond
    2015-07-24 FDASUGARPROPOSAL

TOP

  • Day/
  • Week/
  • Original/
  • Recommand

Updated